A narrative review outlines the need for earlier and broader pediatric trial enrollment while profiling a few ongoing studies and other signs of potential progress.
How to Counsel MS Patients on Disease-Modifying Therapy About COVID-19
COVID-19 poses particular concerns for people being treated for neuroimmunologic disorders like multiple sclerosis. Our expert clinicians offer nuanced guidance on counseling patients about balancing risks and benefits.
New BEAT-MS Trial Stages Direct Comparison of Stem Cells and Biologics for Relapsing MS
Immunosuppression followed by hematopoietic stem cell transplant has shown potent, long-lasting efficacy for relapsing multiple sclerosis in early studies. Now comes a six-year phase 3 trial.
AAN Updates Its Guideline on Vaccines in Multiple Sclerosis: What Providers Need to Know
A slew of new disease-modifying therapies in the 17 years since the last guideline prompted the update. A co-author of the new document shares takeaways.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Generics and Biosimilars in Multiple Sclerosis: Navigating a New Therapy Landscape
The first generic forms of disease-modifying therapies for MS are here, with more expected soon. Dr. Jeffrey Cohen reflects on how clinicians might best approach them.